Hyderabad,
January 23, 2026 : Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389),
a leading Indian pharmaceutical company, today announced a significant
milestone in its research and development pipeline with the successful
advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients
(APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.

The
development marks an important step in Sigachi’s strategic focus on expanding
its presence in complex, high-value specialty APIs, aligned with global demand
for advanced therapies in rare and chronic disease segments.

The
global cystic fibrosis therapeutics market is estimated to exceed USD 10
billion, driven by growing adoption of next-generation modulator therapies,
long-term treatment requirements, and strong pricing resilience. Against this
backdrop, Sigachi’s entry into CF APIs positions the Company in a structurally
strong and innovation-led therapeutic segment with long-term demand visibility.

Based
on internal market assessment and strategic evaluation, the Company is actively
exploring strategic collaborations with formulation innovators for R&D and
future commercial supply of these CF APIs. Subject to successful partnerships
and market progression, the Company estimates a revenue potential of
approximately ₹250 crore per annum commencing from Q4 FY2026–27, making this
portfolio a meaningful growth driver.

Commenting
on the development, Lijo Chacko, Deputy Group CEO, Sigachi Industries
Limited, said, “This milestone reflects Sigachi’s focused strategy of
building depth in complex and differentiated APIs with long-term growth
visibility. Our continued investments in R&D and partnerships are aimed at
strengthening our position in high-entry-barrier specialty segments and
creating sustainable value for stakeholders.”

The
CF API combination involves advanced chemistry, multi-step synthesis, and
specialised reactions, resulting in high technological complexity and
significant barriers to entry, thereby limiting competitive intensity and
reinforcing Sigachi’s capabilities in complex API manufacturing.

Further
strengthening long-term visibility, the innovator patent protection for
Vanzacaftor extends until 2039, providing sustained collaboration-led
commercial opportunity and revenue stability within the cystic fibrosis
therapeutic space.

Sigachi
Industries continues to focus on strengthening its core businesses while
selectively scaling innovation-driven, high-value opportunities aligned with
its long-term growth strategy.

About
Sigachi Industries Ltd

Sigachi
Industries Limited is a global player in the pharmaceutical industry dedicated
to pioneering advancements in Active Pharmaceutical Ingredients (APIs),
Intermediates, Excipients, vitamin-mineral blends, and Operations and
Management (O&M) services. The company’s diverse product portfolio is
manufactured in 5 multilocational facilities, viz. Telangana, Gujarat, and
Karnataka. Aligned with its ethos of customer centricity, Sigachi established
subsidiaries in UAE and USA to be closer to its clients and improve
responsiveness. With a strong focus on innovation, quality, and regulatory
compliance, we leverage cutting-edge technology and global expertise to develop
high-value pharma, food and nutrition solutions that enhance healthcare
outcomes. Committed to excellence, we continuously invest in Research and
Development, ensuring the highest standards of quality and safety. With 36
years of industry experience, Sigachi is a trusted partner for pharmaceutical
and nutraceutical companies spread across 65+ countries. At Sigachi, we
collaborate with healthcare partners, regulatory bodies, and global
stakeholders to expand access to reliable, high-quality pharmaceutical
ingredients.